2382: 2026 Could Be a Defining Year for POLB 001 and Oral GLP-1

from The Vox Markets Podcast · host Vox Markets Podcast

Poolbeg Pharma CEO Jeremy Skillington discusses progress across POLB 001, including regulatory clearance, IP protection, US payer research and the path towards interim clinical data in cancer immunotherapy-induced CRS. He also updates investors on the company’s cash runway, partnering strategy and the potential commercial opportunity in oral GLP-1 therapies.

NOW PLAYING

0:00 12:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Vox Markets Podcast?

This episode is 12 minutes long.

When was this The Vox Markets Podcast episode published?

This episode was published on April 28, 2026.

What is this episode about?

Can I download this The Vox Markets Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!